Description
IMPORTANT SAFETY INFORMATION
BRAVECTO Chews: indicated for dogs 8 weeks of age and older. The most commonly reported adverse reactions include itching, diarrhea, vomiting, decreased appetite, elevated ALT, lethargy, and weight loss. BRAVECTO 1-MONTH is ineffective against A. Americanum in puppies under 6 months of age. BRAVECTO Chews for Dogs: The most commonly reported adverse reactions include vomiting, lethargy, diarrhea, anorexia, and pruritus. In some cases, adverse events have been reported following use in breeding females.
BRAVECTO is not effective for the 12-week duration in puppies or kittens less than 6 months of age. BRAVECTO Chews and Topical Solution for dogs is ineffective against the lone star tick beyond 8 weeks of dosing.
All BRAVECTO products contain fluralaner, which is a member of the isooxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving isooxazoline-class drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. Neurologic adverse reactions have been reported in cats receiving isooxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders.
